Antihypertensive medications for risk reduction of first and recurrent ischemic stroke

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 6, 2004, Pages 867-876

  Padma, Vasamtha ^a   Fisher, Marc ^b   Moonis, Majaz ^b  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Angiotensin receptor blockers; Angiotensin converting enzyme inhibitors; Ischemic stroke; Recurrent stroke

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; CANDESARTAN; CANDESARTAN HEXETIL; CHLORTALIDONE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; UREA; VALSARTAN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COUGHING; CREATININE BLOOD LEVEL; DIZZINESS; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; FATIGUE; HEADACHE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY PERFUSION; PERFUSION PRESSURE; RECURRENT DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; UREA NITROGEN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRIMARY PREVENTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 8644248964     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.6.867     Document Type: Review

References (65)

1. Bonita R. Stroke prevention: a global perspective. In: Stroke Prevention. Norris JW, Hachinski V (Eds). Oxford University Press, Oxford, UK, 259-274 (2001).
2. World Health Organization. World Health Report 1999. World Health Organization, Geneva, Switzerland (1999).
3. Bonita R. Epidemiology of stroke. Lancet 339, 342-344 (1992).
4. Hankey G, Warlow C. Treatment and secondary prevention of stroke: evidence, costs and effects on individuals and populations. Lancet 354, 1457-1463 (1999).
5. Prospective Studies Collaboration. Cholesterol, diastolic blood pressure and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet 346, 1647-1653 (1995).
6. Collins R, MacMahon S. Blood pressure, antihypertensives drug treatment and the risks of strokes and of coronary heart disease. Br. Med. Bull. 50, 272-298 (1994).
7. Gueyffier F, Boutitie F, Boissel JP et al. for the INDANA Investigators. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men: a meta-analysis of individual patient data from randomized, controlled trials. Ann. Intern. Med. 126, 761-767 (1997).
8. Lawes CMM, Bennett DA, Feigin VL, Rodgers A. Blood pressure and stroke. An overview of published reviews. Stroke 35(4), 1024-1033 (2004).
9. MacMahon S, Peto R, Cutler J et al. Blood pressure, stroke and coronary heart disease, I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335, 765-774 (1990).
10. Rodgers A, MacMahon S, Yee T et al. Blood pressure, cholesterol and stroke in Eastern Asia. Lancet 352, 1801-1807 (1998).
11. Staessen JA, Gasowski J, Wang JIG et al. Risks of untreated and treated isolated systolic hypertension in the elderly- meta-analysis of outcome trials. Lancet 355, 865-872 (2000).
12. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvacular complications in Type 2 diabetes. Br. Med. J. 317, 713-720 (1998).
13. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial group. Lancet 351, 1755-1762 (1998).
14. MacMahon S, Rodgers A. The effects of antihypertensive treatment on vascular disease: reappraisal of evidence in 1994. Trends Vasc. Med. 4, 265-271 (1994).
15. Rossi GP, Rossi A, Saccheto A, Pavan E, Pessina AC. Hypertensive cardiovascular disease and renin-angiotensin system. Stroke 26, 170-176 (1995).
16. Farmer JA, Torre-Amione G. The renin-angiotensin system as a risk factor for coronary artery disease. Curr. Atheroscler. Res. 3, 117-124 (2001).
17. Kario Y, Kanai N, Saito K, Ngo N, Matsuo T, Shimada K. Ischemic stroke and the gene angiotensin-converting enzyme in Japanese hypertensives. Circulation 93, 1630-1633 (1996).
18. Markus HS, Barley J, Lunt R et al. Angiotensin-converting enzyme gene deletion polymorphism: a new risk factor for lacunar stroke but not carotid atheroma. Stroke 26, 1329-1333 (1995).
19. Catto A, Carter AM, Barrett JA et al. Angiotensin-converting enzyme insertion/deletion polymorphism and cerebrovascular disease. Stroke 27, 435-440 (1996).
20. Sethi AA, Tybjaerg-Hansen A, Moes Gronholdt ML, Steffensen R. Schnor P, Nordestgaard BG. Angiotensin mutations and risk of ischemic heart disease, myocardial infarction, and ischemic cerebrovascular disease. six case-control studies form the Copenhagen City Heart Study. Ann. Intern. Med. 134, 941-954 (2001).
21. Schmidt H, Fazekas F, Kostner GM, Van Duijn CM, Schmidt R. Angiotensinogen gene promoter haplotype and macroangiopathy related cerebral damage. results of the Austrian stroke Prevention Study. Stroke 32, 405-412 (2001).
22. Schmieder RE, Marttus P, Klinbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. J. Am. Med. Assoc. 275, 1507-1513 (1996).
23. Swedberg K, Held P, Kjekshus J, Rasmussen K, Ryden L, Wedel H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the CoOperative New Scandinavian ENalapril SUrvival Study II (CONSENSUS II). N. Engl. J. Med. 327, 678-684 (1992).
24. Ruilope LM, Campo C, Rodicio JL. Blood pressure control, proteinuria and renal outcome in chronic renal failure. Curr. Opin. Nephrol. Hypertens. 7, 145-148 (1998).
25. Pfeffer MA, Braunwald E, Moyce LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N. Engl. J. Med. 327, 669-677 (1992).
26. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renoprotoctive properties of ACE inhibition in nondiabetic nephropathies with nonnephrotic proteinuria. Lancet 354, 359-364 (1999).
27. Schiffrin EL, Deng LY, Larochelle P. Effects of a β-blocker or an angiotensin-converting enzyme inhibitor on small arteries in essential hypertension. Hypertension 23, 83-91 (1994).
28. Schiffrin EL, Deng LY, Larochelle P. Progressive improvement in the structure of resistance arteries of hypertensive patients after 2 years of treatment with an angiotensin I converting enzyme inhibitor: comparison with effects of a β-blocker. Am. J. Hypertens. 8, 229-236 (1995).
29. Thybo NK, Stephens N, Cooper A, Aalkjaer C, Heagerty AM, Mulvany MJ. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension 25, 474-481 (1995).
30. Schiffrin EL, Deng LY. Comparison of effects of angiotensin I-converting enzyme inhibition and β-blockade for 2 years on function of small arteries from hypertensive patients. Hypertension 25, 699-703 (1995).
31. Rizzoni D, Muiesan ML, Porteri E et al. Effects of long-term and hypertensive treatment with lisinopril on resistance arteries in hypertensive patients with left ventricular hypertrophy. J. Hypertens. 15, 197-204 (1997).
32. Schiffrin EL, Park J-B, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 101, 1653-1659 (2000).
33. Bosch J, Yusuf S, Pogue J et al. Use of ramipril in preventing stroke: double-blind randomized trial. Br. Med. J. 324, 699-708 (2002).
34. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor ramipril on cardiovascular events in high-risk patients. N. Engl. J. Med. 342, 145-153 (2000).
35. Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). J. Renin Angiotensin Aldosterone Syst. 1(1), 18-20 (2000).
36. Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S, for the HOPE investigators. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med. 134, 629-636 (2002).
37. The African American Study Of Kidney Disease and hypertension (AASK) Study Group. Effect of ramipril versus amlodepine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. J. Am. Med. Assoc. 285, 2719-2728 (2001).
38. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patient treated with ramipril and vitamin E (SECURE). Circulation 103, 919-925 (2001).
39. Wakeman AP. Ramipril in stroke prevention: benefits were considerably overstated. Br. Med. J. 324, 687-688 (2002).
40. van Gijn J. The PROGRESS trial: preventing strokes by lowering blood pressure in patients with cerebral ischemia. Stroke 33, 319-324 (2002).
41. PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with previous stroke or transient attack. Lancet 358, 1033-1041 (2001).
42. Black HR. The evolution of low dose diuretic therapy: the lessons from clinical trials. Am. J. Med. 101(Suppl. 3A), S47-S52 (1996).
43. Walters MR, Bolster A, Dyker AG, Lees KR. Effect of perindopril on cerebral and renal perfusion in stroke patients with carotid disease. Stroke 32, 473-478 (2001).
44. Fox KM, EURopean trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicenter trial (The EUROPA study). Lancet 362, 782-788 (2003).
45. White HD. Should all patients with coronary disease receive angiotensin-converting enzyme inhibitors? Lancet 362, 755-756 (2003).
46. ALLHAT officers and coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J. Am. Med. Assoc. 288, 2981-2997 (2002).
47. Wing LM, Revd CM, Ryan P et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med. 348, 583-592 (2003).
48. Chatellier G, Mann JFE, Passa P, Mènard J, DIABHYCAR Study investigators. Effects of low dose ramipril on cardiovascular and renal outcomes in patients wit Type 2 diabetes and raised excretion of urinary albumin: randomized, double-blind placebo-controlled trial (the DIABHYAR study) Br. Med. J. 328, 495-509 (2004).
49. Fournier A, Ghitu A, Darabont R et al. Duality of angiotensin II receptors and risk for stroke and cancer: what is the connection? Presse Med. 28(17), 918-922 (1999).
50. Lopez-Farre A, Sanchez de Miguel L, Monton M et al. Angiotensin II AT(I) receptor antagonists and platelet activation. Nepbrol. Dial. Transplant. 16(Suppl. 1), 45-49 (2001).
51. Cohn JN. ACE inhibition and vascular remodeling of resistance vessels: vascular compliance and cardiovascular implications. Heart Dis. 2, S2-S6 (2002).
52. Dahlof B, Devereux RB, Kjeldsen SE et al. The LIFE Study Group. Lancet 359, 995-1003 (2002).
53. Vacher E, Richer C, Giudiceli JF. Effects of losartan in cerebral arteries in stroke-prone spontaneously hypertensive rats. J. Hypertens. 14(11), 1341-1348 (1996).
54. Hansson L, Lithell H, Skoog I et al. The Study of Cognition and Prognosis in the Elderly (SCOPE). The International Hypertension Society/European Hypertension Society Meeting. Prague, Czech Republic, 27 June 2002.
55. Schraeder J, Luders S, Kulschewski A et al. (ACCESS Study Group). The ACCESS Study - evaluation of Acute Candesartan CilexEtil therapy in Stroke Survivors. Stroke 34, 1699-1707 (2003 ).
56. Cheung RT, Hachinski V. The insula and cerebrogenic sudden death. Arch. Neurol. 57, 1685-1688 (2000).
57. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis Am. J. Cardiol. 89(2A), A18-A25 (2002).
58. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive pateints at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial. Lancet 363, 2022-2031 (2004).
59. Staessen JA. Wang JG, Thijs L Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 358, 1305-1315 (2001).
60. Kario K, Shimada K, Pickering TG. Clinical implication of morning blood pressure surge in hypertension. J. Cardiovasc. Pharmacol. 42(Suppl.), S87-S91 (2003).
61. Kario K, Pickering TG, Umeda Y et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 107, 1401-1406 (2003).
62. Eguchi K, Kario K, Hoshide Y et al. Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients. Am. J. Hypertens. 17, 112-117 (2004).
63. Gorelick PB, Sacco RL, Smith DB et al. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. J. Am. Med. Assoc. 281, 1112-1120 (1999).
64. Goldstein LB, Adams R, Becker K et al. Primary prevention of ischemic stroke: a statement for healthcare professionals from the stroke Council of the American Heart Association. Circulation 103, 163-182 (2001).
65. Sokol SI, Portnay EL, Curtis JP et al. Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke. Neurology 63, 208-213 (2004).